M&AEuropean Commission calls for reversal of Illumina’s $7bn Grail mergerLatest News The European Commission has now recommended concrete steps that, while not yet final, would require Illumina to "swiftly" reverse its controversial $7.1bn acquisition of Grail. Read more 6 December 2022 https://european-biotechnology.com/wp-content/uploads/2024/04/the-EU-commissioners-2021.jpg 540 960 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2022-12-06 09:07:002024-07-15 13:33:43European Commission calls for reversal of Illumina’s $7bn Grail merger